Emerging studies on retatrutide, a dual activator for glucagon-like peptide-1 and gastric inhibitory polypeptide, indicate promising results in treating obesity and type 2 diabetes. Early data from clinical trials show notable diminutions in body weight and improved glucose levels. Ongoing examination is directed on long-term harmlessness and effic